Overcoming the Limitations of Acute Kidney Injury (AKI) Diagnostics in the Emergency Department: the Biomarker Proenkephalin for Early Recognition of AKI
Acute Kidney Injury is a serious…
Sepsis in the Emergency Department: Recognizing High-Risk Patients With the Biomarker Bioactive Adrenomedullin
Recognizing the high risk sepsis patients at the Emergency Department (ED) poses a…
Using bio-ADM and penKid for Optimization of AHF Management in Daily Clinical Practice
Acute Heart Failure (AHF) is a leading cause of hospitalization in the elderly population and it is commonly…
The Implementation of a Novel Kidney Function Biomarker in Clinical Routine
Even though AKI affects 1 in 3 patients in the intensive care units, there is a significant unmet need generated by late…
Point-of-care Diagnostics in the Emergency Department: Better Patient Management
Near patient diagnostics can greatly improve the time to intervention and the outcomes for the severely sick patients…
Using Proenkephalin as a Novel Biomarker to Estimate GFR
The standard of care to determine kidney function has significant limitations, including late detection of changes in kidney function and the…
For higher throughput, IVD tests for SphingoTec’s proprietary biomarkers for critical care and preventive medicine are made available as sphingotest® microtiterplate assays.
SphingoTec is pleased to announce the following appointments to its management team: Deborah Bergmann as Managing Director and Chief Executive Officer (CEO), Dr. Florian Uhle as Managing Director and…
Bioactive Adrenomedullin (bio-ADM), is a dynamic biomarker for the real time assessment of endothelial function. Loss of endothelial function is causing the formation of edema, shock and subsequent…
PenKid Whitepaper
The whitepaper covers practical insights on the AKI diagnostics and highlights the scientific evidence for penKid, a kidney function biomarker.
Click here to download the…
